rabbit antibodies against fli1 (Cell Signaling Technology Inc)

Structured Review

Rabbit Antibodies Against Fli1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit antibodies against fli1/product/Cell Signaling Technology Inc
Average 93 stars, based on 1 article reviews
Images
1) Product Images from "Total glucosides of paeony inhibits liver fibrosis and inflammatory response associated with cirrhosis via the FLI1/NLRP3 axis"
Article Title: Total glucosides of paeony inhibits liver fibrosis and inflammatory response associated with cirrhosis via the FLI1/NLRP3 axis
Journal: American Journal of Translational Research
doi:

Figure Legend Snippet: Primers used in RT-qPCR
Techniques Used:

Figure Legend Snippet: TGP can promote the expression of transcription factor FLI1. (A) Microarray analysis of differential gene expression profiles in the liver of mice treated with CCl4 or CCl4 + TGP. (B, C) Detection of FLI1 expression in liver tissues of mice by RT-qPCR (B) and Western blot (original, full-length gel and blot images can be found in the Supplementary Figure 1) (C). (D, E) Detection of FLI1 mRNA and protein expression after tail vein injection of AAV-shFLI1 or AAV-NC in CCl4 + TGP-treated mice by RT-qPCR (D) and Western blot (original, full-length gel and blot images can be found in the Supplementary Figure 1) (E). Data are displayed as the mean ± SD (n = 6) and compared by one-way ANOVA. *P < 0.05, **P < 0.01. TGP, total glucosides of paeony; FLI1, friend leukemia integration 1 transcription factor; CCl4, carbon tetrachloride; AAV, adeno-associated virus; NC, negative control.
Techniques Used: Expressing, Microarray, Quantitative RT-PCR, Western Blot, Injection, Negative Control

Figure Legend Snippet: AAV-shFLI1 inhibits the effects of TGP on liver fibrosis and inflammatory responses associated with cirrhosis in mice. Adenoviruses AAV-shFLI1 or AAV-NC were injected into CCl4 + TGP-treated mice via tail vein injection. A. The serum levels of ALT and AST measured using ELISA in mice. B. The extent of liver tissue damage in CCl4 + TGP-treated mice assessed using HE staining. C. Fibrosis in the liver of CCl4 + TGP-treated mice measured using Masson’s staining. D. Immunohistochemical analysis of α-SMA positivity in liver tissues of CCl4 + TGP-treated mice. E. Apoptosis in CCl4 + TGP-treated mice measured using TUNEL assay. F. The determination of TNF-α, IL-1β and IL-6 in the serum of CCl4 + TGP-treated mice examined using ELISA assay. Adenoviruses AAV-shFLI1 or AAV-NC were injected into olive oil-treated mice via tail vein injection. G. Detection of FLI1 protein expression in liver tissues of olive oil-treated mice by Western blot (original, full-length gel and blot images can be found in the Supplementary Figure 1). H. The extent of liver tissue damage in olive oil-treated mice assessed using HE staining. I. Fibrosis in the liver of olive oil-treated mice measured using Masson’s staining. J. Immunohistochemical analysis of α-SMA positivity in liver tissues of olive oil-treated mice. Data are displayed as the mean ± SD (n = 6) and compared by one-way ANOVA or unpaired t test. *P < 0.05, **P < 0.01. FLI1, friend leukemia integration 1 transcription factor; CCl4, carbon tetrachloride; AAV, adeno-associated virus; NC, negative control; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ELISA, enzyme-linked immunosorbent assay; HE, hematoxylin-eosin; α-SMA, alpha skeletal muscle actin; TUNEL, terminal deoxynucleotidyl transferase (TdT)-mediated 2’-Deoxyuridine 5’-Triphosphate (dUTP) nick end labeling; TNF-α, tumor necrosis factor alpha; IL, interleukin.
Techniques Used: Injection, Enzyme-linked Immunosorbent Assay, Staining, Immunohistochemical staining, TUNEL Assay, Expressing, Western Blot, Negative Control, End Labeling

Figure Legend Snippet: FLI1 represses NLRP3 transcription. (A) Pathway enrichment analysis of downstream targets of FLI1. (B) Protein-protein interactions (PPI) enrichment analysis of downstream targets of FLI1. (C) FLI1 has a possible binding relation with the NLRP3 promoter region. (D, E) Expression of NLRP3 in the liver of mice with cirrhosis by RT-qPCR (D) and Western blot (E) (original, full-length gel and blot images can be found in the Supplementary Figure 1). (F, G) Expression of FLI1 and NLRP3 in LPS-treated mouse hepatocytes assessed by RT-qPCR (F) and Western blot (G) (original, full-length gel and blot images can be found in the Supplementary Figure 1). (H, I) Effects of transfection with oe-FLI1 on FLI1 and NLRP3 expression in LPS-treated hepatocytes by RT-qPCR (H) and Western blot (I) (original, full-length gel and blot images can be found in the Supplementary Figure 1). (J) Binding site of FLI1 on the NLRP3 promoter. (K) The effect of FLI1 on NLRP3 transcription evaluated using the luciferase reporter assay. (L) The binding relation between FLI1 and NLRP3 promoter measured using ChIP-qPCR. Data are displayed as the mean ± SD of three independent experiments (n = 6) and analyzed by unpaired t test or one-way/two-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001. FLI1, friend leukemia integration 1 transcription factor; NLRP3, nod-like receptor protein 3; LPS, lipopolysaccharide; ChIP, chromatin immunoprecipitation.
Techniques Used: Binding Assay, Expressing, Quantitative RT-PCR, Western Blot, Transfection, Luciferase, Reporter Assay, Chromatin Immunoprecipitation

Figure Legend Snippet: Silencing of NLRP3 mitigates liver fibrosis and inflammatory response in mice treated with AAV-shFLI1 and TGP. TGP-treated mice were injected with AAV-NC + AAV-shFLI1, AAV-NC + AAV-shNLRP3, AAV-shFLI1 + AAV-sh-NLRP3 via tail vein injection. A. Detection of FLI1 and NLRP3 protein expression in liver tissues of mice (original, full-length gel and blot images can be found in the Supplementary Figure 1) using Western blot. B. The serum levels of ALT and AST were assessed by ELISA in mice. C. The extent of liver tissue damage in mice assessed using HE staining. D. Fibrosis in the liver of mice measured using Masson’s staining. E. Immunohistochemical analysis of α-SMA positivity in liver tissues of mice. F. Apoptosis in mice with liver cirrhosis measured using TUNEL assay. G. The determination of TNF-α, IL-1β and IL-6 in the serum of mice examined using ELISA assay. Data are displayed as the mean ± SD (n = 6) and analyzed by one-way/two-way ANOVA. *P < 0.05, **P < 0.01. FLI1, friend leukemia integration 1 transcription factor; NLRP3, nod-like receptor protein 3; AAV, adeno-associated virus; TGP, total glucosides of paeony; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ELISA, enzyme-linked immunosorbent assay; HE, hematoxylin-eosin; α-SMA, alpha skeletal muscle actin; TUNEL, terminal deoxynucleotidyl transferase (TdT)-mediated 2’-Deoxyuridine 5’-Triphosphate (dUTP) nick end labeling; TNF-α, tumor necrosis factor alpha; IL, interleukin.
Techniques Used: Injection, Expressing, Western Blot, Enzyme-linked Immunosorbent Assay, Staining, Immunohistochemical staining, TUNEL Assay, End Labeling